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ABSTRACT 
    The American Society of Human Genetics (ASHG) recommends that testing for 
adult onset conditions be deferred until adulthood because of the potential for psychological 
harm combined with lack of medical utility. ASHG’s 2016 DNA Day Essay Contest asked 9-
12th graders to defend or refute this position. 1241 essays were submitted. 572 students 
defended ASHG’s position statement, while 554 argued against. Essays that addressed 
Alzheimer’s disease (AD) and BRCA-related Hereditary Breast and Ovarian Cancer 
syndrome were qualitatively analyzed for themes related to the argued position. 64.4% of 
students argued for deferred testing of AD, and 46.1% of students argued for deferred testing 
of BRCA. Relevant themes include the availability or lack of medical intervention, potential 
psychological benefit or consequence, and genetic testing variability and uncertain 
predictability. This data suggests that minors have thoughtful and insightful opinions that 
should be taken into consideration when considering predictive genetic testing. 
KEYWORDS: Predictive testing, presymptomatic testing, minors, adolescents, adult onset, ASHG, 
ethics, perspectives, attitudes, genetic testing 
  
INTRODUCTION 
The introduction of genetic testing into clinical care has brought with it many obvious 
benefits, but also a great deal of uncertainty. In particular, it has raised ethical concerns about 
the potential downsides of predictive information. Predictive testing, done in the absence of 
any sign or symptom of disease, requires considerable forethought. While testing for adult 
onset disorders is accepted as a reasonable option for adults who wish to know their risk for 
late-onset conditions, a cautious approach is taken when considering predictive testing for 
children and adolescents. Disputes arise when clinicians, families, or minors themselves 
consider testing for adult onset conditions before symptoms present and when there is no 
impact on medical care before adulthood.  
Scientists are increasingly identifying genes and other biological markers that can 
provide presymptomatic and predictive risk estimates for developing an adult onset disorder 
(Roberts, Cupples, Relkin, Whitehouse, & Green, 2005). Two common examples of adult 
onset disorders are Alzheimer’s disease (AD) and Hereditary Breast and Ovarian Cancer 
Syndrome (HBOC). AD is a degenerative brain disorder that causes behavioral problems and 
gradual loss of memory. The common form of this disease usually presents in people over 
65; however, there is a genetic variant that causes the onset of disease earlier in adulthood.  
Finding that one carried this variant would indicate a predisposition to potentially developing 
symptoms much earlier in life. HBOC is a syndrome most commonly caused by a mutation 
in the BRCA1 gene or BRCA2 gene that results in a dramatically increased lifetime risk of 
developing breast and/or ovarian cancer. 
The debate surrounding presymptomatic testing in minors is complex.  The most 
widely accepted ethical justification for genetic testing of minors is the direct benefit of 
medical intervention or preventative measures (Borry, Stultiens, Nys, Cassiman, & Dierickx, 
2006). In addition, minors and their families may choose to be tested to alleviate uncertainty 
or to develop a long-term plan for the future. Commonly cited reasons to avoid testing are 
fear that this information could create social, emotional, psychological, and educational 
consequences for minors (Borry, et. al., 2006). Because of these and additional concerns, 
clinical guidelines and position papers often discourage presymptomatic and predictive 
testing in minors, including guidelines from the American Society of Human Genetics 
(ASHG), the National Society of Genetic Counselors (NSGC), and the American Academy 
of Pediatric (AAP). Guidelines typically emphasize that the age of testing should be flexible, 
but that genetic testing should be deferred to ensure that adolescents are competent enough to 
make an informed decision (Borry, et. al., 2006).   
For clarity, this paper uses the words “adolescent,” “minor,” “student,” and “young 
person” interchangeably as all-encompassing terms for a high school-aged person, ages 14-
18.  
 
Arguments Against Predictive Testing of Minors 
Reasons to support the deferral of genetic testing until the age of 18 are considered 
extensively throughout the literature. Several studies that have looked at the consequences of 
predictive testing in adolescents assert that the disadvantages are mainly psychological in 
nature  (Bradbury, Patrick-Miller, Ibe, Cummings, Olopade, & Daugherty, 2008). Potential 
psychological consequences that individuals have experienced with early testing are cited 
across studies, including increased disease-related stress and anxiety, distortion of family 
relationships, interference with normal development of self-concept, and feelings of 
unworthiness (Bradbury, et. al., 2008). Additionally, a positive test result has been reported 
to cause a loss of self-esteem, stigmatization, and lowered expectations within the family if 
parents limit horizons for gene-positive minors, resulting in adolescent loss of self-worth 
(Wertz, Fanos, & Reily, 1994). 
Another argument against the genetic testing of minors is that it compromises what is 
often referred to as an “open future.” The right to an open future is an argument based on 
autonomy, and suggests that the minor’s right to make decisions for him or herself as an 
adult should be preserved to the greatest extent possible (Bredenoord, de Vries, & van 
Delden, 2014). This “open future” argument asserts that people have different concepts of 
what a “good life” entails and have differing opinions about the pros and cons of genetic 
testing—therefore, individuals should be able to make their own choices according to their 
own values, and not have those decisions curtailed by parental or other forms of surrogate 
decision making (Bredenoord, et. al., 2014). 
  
Arguments in Favor of Predictive Testing of Minors 
There is a growing need to understand the psychological consequences of predictive 
testing (Michie, Bobrow, & Marteau, 2001). The main argument in support of testing 
adolescents for adult onset disorders is that testing has the potential to impact behaviors that 
will affect their future health (Bradbury, et. al., 2008). Many practitioners believe that some 
adolescents are not only equipped to handle the information, but are also able to take the 
information and act upon it. By engaging in healthy behaviors or starting early surveillance 
and management, studies suggest that they may be able to decrease or postpone their risk of 
developing symptoms of the disease (Aatre & Day, 2011). Some medical professionals 
believe that in certain instances, minors will indeed benefit psychologically from the 
information, giving them both relief of having identified their condition early and a feeling of 
control (Aatre & Day, 2011). Although there is a concern that predictive testing in unaffected 
minors could induce unnecessary anxiety and distress, some data actually suggests the 
opposite, revealing that testing can provide reassurance, lessen uncertainty, and promote a 
healthy sense of control (Aarte & Day, 2011). 
Further, some experts have proposed that genetic testing can have a positive effect on 
relationships, decrease anxiety and depression, and encourage open communication. Through 
such communication, gene-positive minors have the ability to become active participants in 
their health. This may help to reduce stigmatization and ease requests for help if needed in 
the future  (Duncan & Delatycki, 2006; Mand, Gillam, Delatycki, & Duncan, 2012). 
Withholding genetic information may squander the opportunity for a young person to take 
ownership of their genetic status and incorporate it as part of their identity (Anderson, 
Hayeems, Shuman, Szego, Monfared, Bowdin, & Meyn, 2015). 
Another proposed reason to allow predictive genetic testing at a younger age is for 
planning purposes. Early testing allows for parents to properly prepare for their child’s 
future, and allows children time to adjust while still having the oversight and support of their 
parents (Rhodes, 2006). A review of studies described that both healthcare professionals and 
young adults recognized that family and reproductive planning is quickly approaching at the 
time of testing. In order to proactively prepare for one’s future, young adults consider it 
beneficial and necessary to go through the process of predictive genetic testing (Mand, et. al., 
2012). 
  
Current Research on Predictive Testing in Adults and Adolescents 
While there have been many studies on the emotional impact of genetic testing on 
adults, much less is known about the impact on children and adolescents, who are often 
deemed more “vulnerable to emotional distress” than adults (Michie, et. al., 2001). 
In one influential study called the REVEAL (Risk Evaluation and Education for 
Alzheimer’s Disease) study performed by Roberts, Cupples, Relkin, Whitehouse, and Green 
(2005), 162 adults with a family history of AD were randomly assigned to the disclosure of 
results group or the nondisclosure of results group. The final analysis suggested that risk 
assessment and genotype disclosure did not adversely affect the psychological wellbeing of 
the adults in the study. In fact, following risk disclosure, 90% of all participants reported the 
same or lower anxiety regarding their risk of developing AD compared with baseline levels. 
However, the participants with negative results were more likely to report lower levels of 
anxiety. In addition, there was an increase in preventative lifestyle changes in the group that 
tested positive for the high risk allele, APOE4. This study suggests that psychological 
outcomes can be neutral in regard to pre-symptomatic testing, and that some patients will 
actually take the preventative measures despite the overwhelming information. 
    In one of the few studies that examined the emotional impact of predictive genetic 
testing on minors, Michie, Bobrow, and Marteau (2001) focused on individuals tested for 
familial adenomatous polyposis (FAP). The study’s main objective was to determine if 
minors aged 10-16 or adults who received positive results following predictive testing for 
FAP experienced significant levels of anxiety or depression. The 10-16 year-olds who 
received positive results were slightly more anxious and depressed than those who received 
negative results. However, the minors receiving positive or negative results did not show 
higher levels of anxiety or depression than adults in comparable circumstances.  
  
Testing Recommendations in the United States 
    The development of technologies that can test asymptomatic minors for adult onset 
diseases creates a number of ethical and legal issues (American Society of Human Genetics 
& American College of Medical Genetics, 1995). To facilitate agreement on the points of 
contention surrounding these issues, ASHG and the American College of Medical Genetics 
and Genomics (ACMG) jointly released a statement regarding the testing of minors in 1995 
(ASHG & ACMG, 1995).  This publication was influential in guiding clinicians and families 
during a time in which numerous genetic tests were introduced, particularly presymptomatic 
and predictive tests (Botkin, Belmont, Berg, Berkman, Bombard, Holm, Levy, Ormond, Saal, 
Spinner, Wilfond, & McInerney, 2015). 
As knowledge of genetics and genomics continued to grow, so did the public interest 
in issues related to genetic testing and the expanded use of this type of testing (Friedman 
Ross, Saal, David, & Anderson, 2013). As a result, the topic of testing minors was revisited 
in 2015, when ASHG released an independent position statement. A new statement was 
deemed appropriate, given the evolution of testing combined with the mounting questions 
and concerns raised in regards to testing minors (Botkin, et. al., 2015). 
The 2015 ASHG statement recommends that unless there is an available and 
appropriate clinical intervention during childhood, predictive or presymptomatic testing for 
adult onset conditions should be deferred at minimum until the minor is a consenting adult 
who can participate in medical decision making (Botkin, et. al., 2015). However, ASHG 
recommends that providers acknowledge that in some cases, testing might be reasonable after 
thorough consideration and clinical evaluation. In some circumstances, facilitating predictive 
testing for a minor may be justified. For example, if it can alleviate significant psychosocial 
stress within a family or ease life-planning decisions, then testing may be justifiable. Botkin, 
et. al. (2015) noted that empirical research on the psychosocial impact of predictive and 
presymptomatic testing is limited and suggested that more research is necessary for future 
policy recommendations. 
In February of 2017, the National Society of Genetic Counselors (NSGC) updated its 
position statement regarding the genetic testing of minors for adult onset conditions. NSGC 
briefly states that the deferral of predictive testing of minors is preferable, and optimally 
should be deferred when the results will not impact childhood medical decisions or 
management. They also encourage deferring this type of testing until the minor has the 
“capacity” to consider the risks, benefits, and limitations of such testing.  NSGC states, 
“his/her circumstances, preferences, and beliefs [should be taken] into account to preserve 
his/her autonomy and right to an open future” (NSGC, 2017). 
The American Academy of Pediatrics (AAP) also recommends deferring predictive 
testing until adulthood “unless an intervention initiated in childhood may reduce morbidity or 
mortality.” They also add as an exception to this recommendation that testing may be 
deemed appropriate for a family experiencing “significant psychosocial burden” (AAP Policy 
Statement, 2013). 
  
Testing Recommendations in Foreign Countries 
    In general, similar points have been made by genetic societies worldwide that have 
taken a stance on the predictive testing of minors. In Canada, the Canadian Paediatric Society 
(CPS) states that, ideally, the decision to test should be made with the minor, when he/she is 
competent enough to make the decision (CPS, 2003). Though CPS believes that adolescents 
are not able to be completely autonomous in these situations, they recognize that, “it does not 
seem justified…to refuse testing to a fully informed, competent adolescent who is requesting 
[genetic testing]” (CPS, 2003). 
The European Society of Human Genetics (ESHG) and the Human Genetic Society of 
Australasia (HGSA) have made recommendations that “the best interests of the young person 
must prevail” (HGSA, 2014) and the opinion of the minor should be taken into consideration 
“as an increasingly determining factor in proportion to his or her age or degree of maturity” 
(ESHG, 2009). ESHG stresses that well-informed minors with an adequate understanding of 
the test and its potential implications should be considered competent to make the decision 
for his or herself (ESHG, 2009). ESHG and HGSA suggest that predictive testing for an adult 
onset condition is acceptable only if there are available preventative measures that can be 
taken (ESHG, 2009, HGSA, 2014).   
Compared to the United States, Europe, and Canada, the age at which minors are 
considered autonomous is much younger in Australia. In fact, the HGSA does not 
recommend a specific age to differentiate between who can make an informed decision and 
who cannot—each request for testing requires “individual assessment” (HGSA, 2014). In 
Australia, adolescents are divided into immature and mature youths based on their cognitive 
capacity and psychosocial maturity, and are then deemed able to make fully formed decisions 
after a full psychosocial assessment (HGSA, 2014). 
  
The Need for Adolescent Opinions 
With the limited research focused on the predictive testing of minors, existing 
guidelines are based on suggestions and speculation by clinicians and bioethicists. Notably, 
there is a voice lacking in this discussion: the adolescents themselves. The voices of young 
adults continue to be scarce despite the important role their opinions play in shaping existing 
guidelines and practices (Duncan, Gillam, Savulescu, Williamson, Rogers, & Delatycki, 
2008).  Thus, the focus of our project is to unveil adolescent perspectives regarding genetic 
testing for adult onset conditions. More specifically, we seek to uncover how their opinions, 
as reflected in essays written by minors for ASHG’s annual DNA Day Essay Contest, align 
with ASHG’s position statement on genetic testing of minors. 
 
MATERIALS & METHODS 
Study Design 
Essays were submitted by 9th-12th grade students (roughly ages 14-18) to ASHG’s 
annual 2016 international DNA Day Essay Contest. Essays were thematically analyzed using 
a mixed-methods approach. This analysis was used to investigate reasons why minors would 
defer or not defer genetic testing for adult onset disease. Demographic information including 
gender, grade, and submission location were also analyzed. All essays were uploaded into the 
qualitative analysis program Atlas. Qualitative analyses were conducted using a grounded 
theory approach to assess minors’ views and arguments for and against testing for adult onset 
conditions.   
  
Participants & Essay Question 
ASHG’s 2016 DNA Day essay contest question was as follows: 
Choose a genetic test that is currently available for a condition or disease that does not cause 
symptoms until adulthood (i.e., an adult-onset condition such as hereditary breast cancer). 
Describe how the test works and how certain the test results are. Then, either defend or refute 
the recommendation below from ASHG’s recent position statement on pediatric genetic 
testing. 
 
“Adolescents should be encouraged to defer predictive or pre-dispositional 
testing for adult-onset conditions until adulthood because of the complexity 
of the potential impact of the information at formative life stages.” 
  
Teachers entered essays on behalf of their students, and a total of 1241 essays were 
submitted. Teachers could submit essays from up to six students per class for up to three 
classes.  Participants were informed that essays might be used for research purposes. This 
study received an exemption from the Sarah Lawrence College Institutional Review Board 
(IRB) in April 2016 along with an approval from the Geisinger Health System IRB in March 
2016. 
  
Initial Evaluation of Data 
All essays were categorized by grade, sex, chosen disease, and whether or not the 
student chose to defer testing until adulthood. Essays that did not focus on a single disease 
were titled ‘None’ in the disease category, and the essays that did not pick defer or not defer 
were labeled ‘Other.’ To ensure accuracy, 150 essays were randomly selected to cross-check 
labeling.   
Once the essays were labeled and cross-checked, they were grouped into categories 
based on their content. The essays that were marked ‘Other’ or ‘None’ were reviewed to 
determine if the information could be used to identify a position regarding the testing of 
minors. A total of 77 essays that did not contribute valid information were discarded. 
Reasons for discarding None/Other essays included: 
·       Essay did not address essay prompt or focused on a different topic 
·       Essay was illegible or unintelligible    
·       Essay did not state an opinion 
·       Essay misinterpreted question/ASHG policy 
Reasons for keeping None/Other essays included: 
·       Essay indicated personal/family/individual choice 
·       Essay showed an understanding of the question and represented both sides of the 
argument without choosing a single side 
Decisions were made by consensus among all coders. Essays that were kept were uploaded to 
Atlas and remained in a separate category named ‘None/Other.’ 
 
Developing Codebook and Analysis Framework 
To create the codebook, the three most common disorders were identified (HD, AD, 
& BRCA), and all essays referencing those disorders were assigned two readers. Themes and 
categories based on the essays’ content were identified and served as the basis for an 
inductive data analysis. Lists of topics were assembled by each coder and then combined to 
build a holistic picture of the essays’ content. Coders continued reading until a saturation 
point was reached when no new themes emerged. Subsequently, coders combined their 
findings and then integrated all themes into categories. An initial codebook was established 
by consensus and reviewed by an external supervisor. 
The clarity of the codes was checked through an iterative process to ensure the codes 
were applied appropriately and consistently. To start, all investigators were given five 
randomly selected sentences to apply the relevant codes. The process was repeated until 
reviewer agreement indicated that the codes were unanimously defined. Next, once the 
codebook was agreed upon, five essays were assessed by each coder separately, and then 
compared. This process was repeated until all readers were consistently applying the same 
codes to the same themes found in the essays. Once inter-rater reliability (IRR) was reached, 
essays were divided among 4 coders to code independently. The IRR was 0.95 alpha (≥0.75 
IRR), allowing the data to be analyzed in Atlas.  
 
Codebook 
The final codebook contained 25 codes (Table I.). Twenty four of the codes have a 
counterpart; for example, Code 1: Psychological benefit to minor is paired with Code 2: 
Psychological risk to minor. Each code consisted of a general category, an explanation of the 
themes/topics that related to that category, and example statements for when to apply the 
code to avoid code drift.  
 
 
Code Number and Code 
1. Psychological benefits to minor 13. Disrupts formative years 
2. Psychological risks to minor 14. Social risks 
3. 
Genetic testing 
variability and 
uncertain 
predictability 
15. Social benefits 
4. 
Genetic testing 
accuracy and 
predictability 
16. Mature and incapable  
5. 
Factual 
genetic/disorder 
information 
17. Immature and capable 
6. Incorrect facts 18. Potential discrimination 
7. Risks to family 19. Necessary to plan/prepare 
8. Benefits to family 20. Unnecessary to plan/prepare 
9. Personal experience with the condition 21. Advancements in science 
10. Personal experience with testing 22. Case-by-case 
11. Medical benefit or prevention 23. Loss of autonomy 
12. No medical benefit or prevention 24. Individual’s choice 
  
25. Family/Parent’s choice 
Table I. The complete list of 25 codes. 
 
Thematic Analysis (ATLAS.ti) 
 Of the 1241 essays submitted, 313 essays that discussed BRCA, Lynch, and 
Alzheimer’s disease (189, 13, and 111, respectively) were thematically coded. For the 
purposes of this analysis, only the essays that discussed BRCA and AD were analyzed for 
thematic content relating to the reasons to defer or not defer genetic testing for adult onset 
conditions. 
 
RESULTS 
There were 1241 student essays submitted to the ASHG DNA Day Essay Contest. 
The majority of submissions (87%) were from the United States while a smaller number of 
essays (13%) were submitted by international students.  Figure 1. depicts the number of 
essays submitted from each US state. Six states submitted no essays. The maximum number 
of essays submitted was 186 (New York). Of the 44 states that participated, the average 
number of essay submissions was 28. 
 
Figure 1. Map of the United States depicting the number of essay submissions.  A darker color correlates 
with a higher number of essay submissions. White indicates no essays were submitted.  
 
Females submitted 67% of the essays and males submitted 37%. The majority of 
essays (88%) were evenly distributed between grades 10-12, and 9th graders represented the 
remaining 12%. Over 100 conditions were discussed by the students, but 60 of them were 
mentioned by only one student.  The five most commonly discussed conditions are listed in 
Table II.  
 
Table II. Five most common adult onset conditions chosen, including discarded essays. 
Across all essays, students were almost evenly split on whether they agreed or 
disagreed with the ASHG recommendation to defer testing until adulthood, as depicted in 
Table III. 
 
Table III. Testing decision breakdown across all essays.  
A statistically significant association was seen between which condition the student 
chose to discuss and whether or not the student supported deferring genetic testing (p<.01). 
While 64.4% of the students who submitted AD essays were in favor of deferring testing, 
only 46.1% of the students who submitted BRCA essays were in favor of deferring testing. 
Similarly, more BRCA essays supported not deferring testing (53.9%) than AD essays 
(35.6%) (Table IV). No association was found between sex or grade and the decision to defer 
or not defer in the comparison of BRCA and AD essays (Appendix A). 
 
Defer vs. Not Defer for Alzheimer's and BRCA 
 Alzheimer’s BRCA Total 
Defer Count 67 83 150 
 
 
%  64.4% 46.1% 52.8% 
Not 
Defer 
Count 37 97 134 
 
 
%  35.6% 53.9% 47.2% 
 Total Count 104 180 284 
%  100.0% 100.0
% 
100.0% 
Chi-square (1) = 8.87, p<.01 
 
Table IV. Chi square table showing percentage breakdown between defer and not defer in Alzheimer’s 
and BRCA essays. Chi-square (1) value was found to be 8.87 with a p value of <.01, making the difference 
between the condition chosen and whether or not to defer significant.   
 
 
Figure 2. Bar graph depicting the number of defers and not defers in Alzheimer’s and BRCA essays. 
Green bars represent BRCA essay choices while blue bars represent Alzheimer’s essay choices.  
 
 AD and BRCA essays were examined for correlations between students’ choices to 
defer or not defer. Table V and VI include the five most commonly used codes and their 
counter code. The top three most commonly used codes were examined for the purpose of 
extracting thematic quotes. 
BRCA Thematic Categories All Defer Not Defer 
Psychological benefits to minor 78 8 67 
Psychological risks to minor 248 179 53 
Genetic testing variability and uncertain predictability 202 144 53 
Genetic testing accuracy and predictability 19 9 10 
Medical benefit/prevention 239 41 185 
No medical benefit/not preventable 78 65 5 
Mature and capable 24 1 23 
Immature and incapable 73 63 7 
Necessary to plan/prepare 100 10 86 
Unnecessary to plan/prepare 13 12 1 
Table V. Top five commonly used codes and their counter code within BRCA essays. Note: the defer and 
not defer columns do not add up to the total because there were None/Other essays included in the “all” 
column. 
 
 
Alzheimer's Thematic Categories All Defer Not Defer 
  Psychological benefits to minor 31 6 21 
 Psychological risks to minor 133 107 16 
 Genetic testing variability and uncertain predictability 162 125 26 
 Genetic testing accuracy and predictability 3 3 0 
 Medical benefit/prevention 66 15 47 
 No medical benefit/not preventable 68 59 6 
 Mature and capable 12 0 10 
 Immature and incapable 26 25 0 
 Necessary to plan/prepare 56 9 44 
 Unnecessary to plan/prepare 7 7 0 
Table VI. Top five commonly used codes and their counter code within AD essays. Note: the defer and 
not defer columns do not add up to the total because there were None/Other essays included in the all 
column. 
 
For the BRCA essay submissions that chose to defer, statements under the codes 
‘psychological risks,’ ‘genetic testing variability and uncertain predictability,’ and ‘no 
medical benefit or prevention’ were mentioned the most. Those who chose to not defer 
discussed ‘medical benefit and prevention,’ ‘necessary to plan or prepare,’ and 
‘psychological benefits’ the most. In two of the six most common codes applied to the defer 
and not defer essays there was a direct contrast: while the defer essays discussed 
‘psychological risks’ and ‘no medical benefit or prevention,’ the not defer essays discussed 
‘psychological benefits’ and ‘medical benefit or prevention’ (Table VII.). 
 
  Essay Totals (189)                            BRCA’s Top Codes  (Number of times code was found within the essays) 
Defer (83) 
 
Psychological Risks 
(179) 
Genetic Testing Variability 
and Uncertain Predictability 
(144) 
No Medical Benefit or   
Prevention (65) 
Not Defer (97) Medical Benefit and Prevention (185) 
Necessary to Plan or 
Prepare (86) 
Psychological Benefits 
(67) 
Table VII. Top three codes represented in BRCA essays in the decision to defer or not defer.  
 
 
In the AD student essays that chose to defer, the most commonly discussed reasons 
were ‘genetic testing variability and uncertain predictability,’ ‘psychological risk,’ and ‘no 
medical benefit or prevention.’ Those who chose to not defer most frequently discussed 
‘medical benefit and prevention,’ ‘necessary to plan or prepare,’ and ‘genetic testing 
variability and uncertain predictability.’ Two of the codes applied to the defer and not defer 
essays directly contrasted with one another: ‘no medical benefit or prevention’ with defer and 
‘medical benefit and prevention’ with not defer, while the code ‘genetic testing variability 
and uncertain predictability’ was used for both (Table VIII.). 
   Essay Totals (111)                            Alzheimer’s Top Codes  (Number of times code was found within the essays) 
Defer (67) 
Genetic Testing Variability 
and Uncertain Predictability 
(125) 
Psychological Risks 
(107) 
No Medical Benefit or 
Prevention (59)  
Not Defer (37) Medical Benefit and Prevention (47) 
Necessary to Plan or 
Prepare (44) 
Genetic Testing Variability 
and Uncertain 
Predictability (26) 
Table VIII. Top three codes represented in AD essays in the decision to defer or not defer.  
 
In both BRCA and AD essays the decision to defer was most commonly associated 
with the same three codes, although the order of the most common and second most common 
codes was reversed. The decision to not defer had the same top two codes in the same order 
(‘medical benefit and prevention’ and ‘necessary to plan or prepare’); however, the third 
most used code for the decision to not defer was not shared between the two conditions 
(‘psychological benefit’ versus ‘genetic testing variability and uncertain predictability’). Of 
note, because there were fewer essays discussing AD than BRCA, the codes were applied 
fewer times overall. 
 There was no association found between the number of times a code was applied and 
a student’s sex or grade. All of the essays contained the code ‘factual genetic/disorder 
information.’ A complete list of correlations can be found in Appendix A. 
 
DISCUSSION 
There were several limitations of this study. Notably, this is not a representative 
sample of adolescents: only 1241 essays were submitted, six states did not submit any essays, 
67% of the essays were submitted by females, and the majority of essays analyzed were from 
the United States (87%). It is unclear whether the essay prompt was assigned to the entire 
class or if only the students who had the motivation to write an essay for the contest entered 
their submissions. In addition, teachers may have hand selected what they believed were the 
best essays to submit. Moreover, only two conditions were analyzed thematically, and these 
two conditions combined only make up half of the essays submitted. It is possible that upon 
further analysis of all essays, different codes could be emphasized.   
The data gathered from these essays suggests that minors are insightful about 
predictive testing for adult onset conditions when given an outlet to express their opinions. 
Upon initial analysis, it seemed that the choice to defer or not defer was almost evenly split. 
However, when examined more thoroughly, their views on deferral were more complex and 
appeared to depend on the condition they chose. It is possible that upon learning about the 
ASHG position statement, students were inclined to inherently agree with a medical 
recommendation, regardless of the disease they chose. Another possibility is that a student’s 
initial opinion concerning genetic testing of minors influenced the condition chosen. 
Additional qualitative analysis helped to identify possible reasons why these disease-specific 
themes emerged. 
 
Defer Essay Themes 
Students who chose to defer testing often cited the same reasons discussed in the 
clinical guidelines. One such theme that presents in both the BRCA and AD essays is 
‘psychological risks.’ One student discussing the psychological risks of deferring BRCA 
testing stated, “Overall, adolescents should not be tested for genetic diseases because of the 
emotional trauma that it can inflict on the person” (Essay 1128, BRCA, Defer).  
It is apparent that when weighing whether or not to defer testing, minors consider the 
emotional and psychological implications of genetic testing. This was noted in an AD essay 
in which a student states, “Because there is no cure and limited treatment for Alzheimer’s 
disease, oftentimes predictive genetic testing leads to depression and psychological 
problems” (Essay 1105, AD, Defer).  The potential adverse psychological outcomes that 
coincide with a positive genetic test result are clearly recognized by students and used to 
defend their stance on deferring testing. 
Even for conditions that have medical management options, ‘no medical benefit or 
prevention’ was chosen as a top code to defer because the disease does not occur until 
adulthood. “In the case of breast and ovarian cancers caused by BRCA mutations, there are 
preventative measures…However, since cancer does not appear until adulthood- the average 
age of diagnosis is 42 for breast and 52 for ovarian cancers (Brose et al, 2002)- this does not 
apply to adolescents,” as one student wrote (Essay 141, BRCA, Defer). This expresses the 
idea that minors may defer testing based on the absence of immediate medical benefit, a 
notion also included in the ASHG guidelines. 
The final most commonly used reason for deferring testing was the variable and 
unpredictable nature of genetic testing. An AD student’s essay states, “It is important to note 
that having the APOE e4 allele does not cause the disease; the presence of the e4 allele is 
only one of the many factors that increase risk of development. Currently, no definitive test 
exists for the discovery of Alzheimer’s disease in a living individual; the only conclusive test 
is an autopsy” (Essay 5, AD, defer). Similarly, a student who chose BRCA argued, “A 
positive test result does not mean that a person will definitely develop the cancers, it only 
indicates that the person has an increased risk” (Essay 934, BRCA, Defer). Because there is 
no straightforward genetic testing result for AD and BRCA, many students suggested that it 
would not be beneficial to get genetic testing as a minor. This argument is not mentioned in 
ASHG’s position statement, but it seems to be important to minors. 
BRCA and AD defer essays had the same three most common codes. Despite 
evidence that the reasons behind their decision to defer were similar, there were significantly 
more students who chose to defer testing for AD than BRCA. A possible reason for this 
finding may be due to the lack of medical surveillance and management options for 
Alzheimer’s disease. By comparison, if someone is found to carry a BRCA mutation, there is 
medical management available; individuals could increase their cancer screening and 
consider prophylactic options. For AD, there are only clinical trials in place as a possible way 
to slow progression of the disease.  
 
Not Defer Essay Themes 
The top two codes used in support of not deferring testing were ‘medical benefit’ and 
‘genetic testing variability and uncertain predictability.’ These codes were the same in both 
BRCA and AD essays. An example of the most common argument states that, “adolescents 
should be encouraged to receive genetic testing if there is a chance they may have the 
BRCA1 or BRCA2 mutations to give them a chance to receive medical care to help prevent 
the development of breast or ovarian cancer in the future” (Essay 1101, BRCA, Not Defer).  
When considering AD, one student wrote, “I believe genetic testing is a positive way to find 
new things out about a certain disorder or mutation in DNA. You should take the opportunity 
of having a test done to prepare yourself for the future to live out a healthier and more 
preventative lifestyle” (Essay 868, AD, Not Defer), demonstrating that there are perceived 
medical benefits to early testing. 
The third most common code noted in association with the decision to not defer 
testing in AD essays was particularly interesting and unexpected. Students mentioned 
‘genetic testing variability and uncertain predictability’ third most despite deciding to not 
defer testing. This may indicate that even though students opted to proceed with testing, they 
found the genetic testing to be uncertain. Possible reasons they decided to not defer despite 
uncertainty in genetic testing were because they found the reasons to have genetic testing 
stronger than the unpredictability of the test. One student relates a version of this idea by 
saying, “It should be encouraged for adolescents to take predictive or pre-dispositional 
testing...They need to be prepared for the reality that they indeed have the mutant gene 
however that does not mean that they are certainly going to get the illness” (Essay 216, AD, 
Not Defer). Another student’s argument supports this idea by saying, “Researchers believe 
genetic testing will never be able to predict the disease with 100 percent accuracy due to 
environmental factors (The Genetics of Disease). Many people find this new technique to 
ease their anticipation that results from the unknown possibility of developing a fatal 
disease” (Essay 499, AD, Not Defer).  
Another reason that ‘genetic testing variability and uncertain predictability’ was used 
repeatedly may be due to the essay prompt itself. The prompt explicitly instructs students to 
“describe how the test works and how certain the test results are.” While researching a 
condition, information on genetic testing uncertainty is readily available. It is likely that 
students included the uncertainty and variable predictability of genetic testing because it was 
required to discuss this aspect of their chosen genetic condition.  
 
Conclusions 
To help evaluate predictive testing on an individual level, genetic counselors should 
play an integral role in explaining the testing options, granting autonomy to the person 
pursuing testing. The theme of protecting autonomy was at the forefront of the national 
guidelines.  The option to pursue genetic testing is important to minors too. As one student 
describes, “I disagree with The American Society of Human Genetics’ position statement. It 
should be encouraged for adolescents to take predictive or pre-dispositional testing. 
However a requirement should be that the teenager must see a genetics counselor who can 
explain to them exactly what it means to get tested and all of the possible outcomes” (Essay 
216, AD, Not Defer). This emphasizes the idea presented by HGSA that states a genetic test 
should be considered as an option on the basis of maturity instead of age after a psychosocial 
assessment. 
It is clear from our analysis of the student essays that adolescents have well-formed 
opinions and insights about predictive genetic testing for adult onset conditions. Current 
guidelines acknowledge some flexibility on the issue of testing a minor; however, this 
flexibility is limited. Minors have shown that their standpoint on this matter is exceedingly 
individual and varies from person to person. Guidelines must acknowledge that minors’ 
opinions are individualized. As an essential piece of the testing process, guidelines should 
recognize that adolescent perspectives are an integral factor when deciding whether or not to 
offer genetic testing to for adult onset conditions. It may be beneficial to implement more 
progressive guidelines reflecting this notion by considering each minor capable of assent on a 
case-by-case basis.  
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Appendix A 
 
Appendix I: Complete list of codes and frequency of use in BRCA essays. 
 
 
Appendix II: Complete list of codes and frequency of use in Alzheimer’s essays. 
